S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL

Podobne zapisy

• PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY
  od: E. Jabbour, i wsp.
  Wydane: (2022-06-01)
• Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor
  od: David Sanford, i wsp.
  Wydane: (2015-12-01)
• The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia
  od: Aziz Nazha, i wsp.
  Wydane: (2013-10-01)
• Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts
  od: Preetesh Jain, i wsp.
  Wydane: (2013-11-01)
• P707: DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) FROM THE PACE AND OPTIC TRIALS
  od: J. Apperley, i wsp.
  Wydane: (2022-06-01)